The polarity and specificity of SARS-CoV2-specific T lymphocyte responses determine disease susceptibility
Abstract Optimal vaccination and immunotherapy against coronavirus disease COVID-19 relies on the in-depth comprehension of immune responses determining the individual susceptibility to be infected by SARS-CoV-2 and to develop severe disease. We characterized the polarity and specificity of circulating SARS-CoV-2-specific T cell responses against whole virus lysates or 186 unique peptides derived from the SARS-CoV-2 or SARS-CoV-1 ORFeome on 296 cancer-bearing and 86 cancer-free individuals who were either from the pre-COVID-19 era (67 individuals) or contemporary COVID-19-free (237 individuals) or who developed COVID-19 (78 individuals) in 2020/21. The ratio between the prototypic T helper 1 (TH1) cytokine, interleukin-2, and the prototypic T helper 2 (TH2) cytokine, interleukin-5 (IL-5), released from SARS-CoV-2-specific memory T cells measured in early 2020, among SARS-CoV-2-negative persons, was associated with the susceptibility of these individuals to develop PCR-detectable SARS-CoV-2 infection in late 2020 or 2021. Of note, T cells from individuals who recovered after SARS-CoV-2 re-infection spontaneously produced elevated levels of IL-5 and secreted the immunosuppressive TH2 cytokine interleukin-10 in response to SARS-CoV-2 lysate, suggesting that TH2 responses to SARS-CoV-2 are inadequate. Moreover, individuals susceptible to SARS-CoV-2 infection exhibited a deficit in the TH1 peptide repertoire affecting the highly mutated receptor binding domain (RBD) amino acids (331-525) of the spike protein. Finally, current vaccines successfully triggered anti-RBD specific TH1 responses in 88% healthy subjects that were negative prior to immunization. These findings indicate that COVID-19 protection relies on TH1 cell immunity against SARS-CoV-2 S1-RBD which in turn likely drives the phylogenetic escape of the virus. The next generation of COVID-19 vaccines should elicit high-avidity TH1 (rather than TH2)-like T cell responses against the RBD domain of current and emerging viral variants..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
bioRxiv.org - (2024) vom: 23. Apr. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
|---|
| doi: |
10.1101/2021.06.18.21258477 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI032047959 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI032047959 | ||
| 003 | DE-627 | ||
| 005 | 20240424105037.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210623s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2021.06.18.21258477 |2 doi | |
| 035 | |a (DE-627)XBI032047959 | ||
| 035 | |a (biorXiv)10.1101/2021.06.18.21258477 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Fahrner, Jean-Eudes |e verfasserin |0 (orcid)0000-0001-6581-8418 |4 aut | |
| 245 | 1 | 0 | |a The polarity and specificity of SARS-CoV2-specific T lymphocyte responses determine disease susceptibility |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Optimal vaccination and immunotherapy against coronavirus disease COVID-19 relies on the in-depth comprehension of immune responses determining the individual susceptibility to be infected by SARS-CoV-2 and to develop severe disease. We characterized the polarity and specificity of circulating SARS-CoV-2-specific T cell responses against whole virus lysates or 186 unique peptides derived from the SARS-CoV-2 or SARS-CoV-1 ORFeome on 296 cancer-bearing and 86 cancer-free individuals who were either from the pre-COVID-19 era (67 individuals) or contemporary COVID-19-free (237 individuals) or who developed COVID-19 (78 individuals) in 2020/21. The ratio between the prototypic T helper 1 (TH1) cytokine, interleukin-2, and the prototypic T helper 2 (TH2) cytokine, interleukin-5 (IL-5), released from SARS-CoV-2-specific memory T cells measured in early 2020, among SARS-CoV-2-negative persons, was associated with the susceptibility of these individuals to develop PCR-detectable SARS-CoV-2 infection in late 2020 or 2021. Of note, T cells from individuals who recovered after SARS-CoV-2 re-infection spontaneously produced elevated levels of IL-5 and secreted the immunosuppressive TH2 cytokine interleukin-10 in response to SARS-CoV-2 lysate, suggesting that TH2 responses to SARS-CoV-2 are inadequate. Moreover, individuals susceptible to SARS-CoV-2 infection exhibited a deficit in the TH1 peptide repertoire affecting the highly mutated receptor binding domain (RBD) amino acids (331-525) of the spike protein. Finally, current vaccines successfully triggered anti-RBD specific TH1 responses in 88% healthy subjects that were negative prior to immunization. These findings indicate that COVID-19 protection relies on TH1 cell immunity against SARS-CoV-2 S1-RBD which in turn likely drives the phylogenetic escape of the virus. The next generation of COVID-19 vaccines should elicit high-avidity TH1 (rather than TH2)-like T cell responses against the RBD domain of current and emerging viral variants. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Carrier, Agathe |e verfasserin |4 aut | |
| 700 | 1 | |a De Sousa, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Drubay, Damien |e verfasserin |4 aut | |
| 700 | 1 | |a Dubuisson, Agathe |e verfasserin |4 aut | |
| 700 | 1 | |a Geraud, Arthur |e verfasserin |4 aut | |
| 700 | 1 | |a Goubet, Anne-Gaëlle |e verfasserin |4 aut | |
| 700 | 1 | |a Ferrere, Gladys |e verfasserin |4 aut | |
| 700 | 1 | |a Haddad, Yacine |e verfasserin |4 aut | |
| 700 | 1 | |a Lahmar, Imran |e verfasserin |4 aut | |
| 700 | 1 | |a Mazzenga, Marine |e verfasserin |4 aut | |
| 700 | 1 | |a Melenotte, Cléa |e verfasserin |4 aut | |
| 700 | 1 | |a Picard, Marion |e verfasserin |4 aut | |
| 700 | 1 | |a Thelemaque, Cassandra |e verfasserin |4 aut | |
| 700 | 1 | |a Cerbone, Luigi |e verfasserin |4 aut | |
| 700 | 1 | |a Lérias, Joana R. |e verfasserin |4 aut | |
| 700 | 1 | |a Laparra, Ariane |e verfasserin |4 aut | |
| 700 | 1 | |a Bernard, Alice |e verfasserin |4 aut | |
| 700 | 1 | |a Kloeckner, Benoît |e verfasserin |4 aut | |
| 700 | 1 | |a Gazzano, Marianne |e verfasserin |4 aut | |
| 700 | 1 | |a Danlos, François-Xavier |e verfasserin |4 aut | |
| 700 | 1 | |a Terrisse, Safae |e verfasserin |4 aut | |
| 700 | 1 | |a Alves Costa Silva, Carolina |e verfasserin |4 aut | |
| 700 | 1 | |a Pizzato, Eugenie |e verfasserin |4 aut | |
| 700 | 1 | |a Flament, Caroline |e verfasserin |4 aut | |
| 700 | 1 | |a Ly, Pierre |e verfasserin |4 aut | |
| 700 | 1 | |a Tartour, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Meziani, Lydia |e verfasserin |4 aut | |
| 700 | 1 | |a Ahmed-Belkacem, Abdelhakim |e verfasserin |4 aut | |
| 700 | 1 | |a Miyara, Makoto |e verfasserin |4 aut | |
| 700 | 1 | |a Gorochov, Guy |e verfasserin |4 aut | |
| 700 | 1 | |a Barlesi, Fabrice |e verfasserin |4 aut | |
| 700 | 1 | |a Pradon, Caroline |e verfasserin |4 aut | |
| 700 | 1 | |a Gallois, Emmanuelle |e verfasserin |4 aut | |
| 700 | 1 | |a Pommeret, Fanny |e verfasserin |4 aut | |
| 700 | 1 | |a Colomba, Emeline |e verfasserin |4 aut | |
| 700 | 1 | |a Lavaud, Pernelle |e verfasserin |4 aut | |
| 700 | 1 | |a Deutsch, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Gachot, Bertrand |e verfasserin |4 aut | |
| 700 | 1 | |a Spano, Jean-Philippe |e verfasserin |4 aut | |
| 700 | 1 | |a Merad, Mansouria |e verfasserin |4 aut | |
| 700 | 1 | |a Scotte, Florian |e verfasserin |4 aut | |
| 700 | 1 | |a Marabelle, Aurélien |e verfasserin |4 aut | |
| 700 | 1 | |a Griscelli, Frank |e verfasserin |4 aut | |
| 700 | 1 | |a Blay, Jean-Yves |e verfasserin |0 (orcid)0000-0001-7190-120X |4 aut | |
| 700 | 1 | |a Soria, Jean-Charles |e verfasserin |4 aut | |
| 700 | 1 | |a Andre, Fabrice |e verfasserin |4 aut | |
| 700 | 1 | |a Chevalier, Mathieu |e verfasserin |4 aut | |
| 700 | 1 | |a Caillat-Zucman, Sophie |e verfasserin |0 (orcid)0000-0002-4535-3550 |4 aut | |
| 700 | 1 | |a Fenollar, Florence |e verfasserin |4 aut | |
| 700 | 1 | |a La Scola, Bernard |e verfasserin |4 aut | |
| 700 | 1 | |a Kroemer, Guido |e verfasserin |4 aut | |
| 700 | 1 | |a Maeurer, Markus |e verfasserin |4 aut | |
| 700 | 1 | |a Derosa, Lisa |e verfasserin |4 aut | |
| 700 | 1 | |a Zitvogel, Laurence |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2024) vom: 23. Apr. |
| 773 | 1 | 8 | |g year:2024 |g day:23 |g month:04 |
| 856 | 4 | 0 | |u https://doi.org/10.1158/2159-8290.cd-21-1441 |x 0 |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2021.06.18.21258477 |x 0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 23 |c 04 | ||